Residency · Residency · Psychiatry

Alcohol Use Disorder: Neurobiology and Pharmacotherapy

Epidemiology and Screening

Prevalence and Burden

Lifetime prevalence: ~29% in the US (past-year ~14%) Third leading preventable cause of death in the US. Only ~7-8% of individuals with AUD receive any treatment. Strong genetic component (~50% heritability) Male:female ratio narrowing over time (historically 2:1, now approaching 1.5:1)

AUDIT (Alcohol Use Disorders Identification Test)

10-item screening instrument developed by the WHO. Covers hazardous drinking, dependence symptoms, and harmful alcohol use. Score >= 8 indicates hazardous or harmful drinking (sensitivity ~90%, specificity ~80%) AUDIT-C: abbreviated 3-item version (consumption questions only); score >= 4 for men, >= 3 for women suggests hazardous drinking. Preferred over CAGE (less sensitive, especially in women and younger patients)

Other Screening Tools

CAGE: 4 items (Cut down, Annoyed, Guilty, Eye-opener); >= 2 positive suggests problem drinking; best as a quick screen in medical settings. Single-question screen: "How many times in the past year have you had 5 or more drinks in a day (men) / 4 or more (women)?" -- any positive response warrants further assessment. NIAAA low-risk drinking guidelines: men <= 4 drinks/day and <= 14/week; women <= 3 drinks/day and <= 7/week.

DSM-5-TR Criteria

>= 2 of 11 criteria within a 12-month period. Criteria span: impaired control (4 items), social impairment (3 items), risky use (2 items), pharmacological indicators (2 items: tolerance, withdrawal) Severity: mild (2-3), moderate (4-5), severe (>= 6) Dimensional model replaced the prior abuse/dependence dichotomy.

Neurobiology of Alcohol Dependence

Neuroadaptation Model

Positive reinforcement phase (binge/intoxication): alcohol activates mesolimbic dopamine pathway (VTA to nucleus accumbens), also enhances GABA transmission and endogenous opioid release. Negative reinforcement phase (withdrawal/negative affect): chronic alcohol use leads to downregulation of GABA receptors and upregulation of glutamate (NMDA) receptors; withdrawal unmasks this excitatory state (anxiety, dysphoria, autonomic hyperactivity) Preoccupation/craving phase: prefrontal cortex dysfunction impairs executive control over cue-driven craving; involves glutamate projections from PFC to nucleus accumbens. The three-stage cycle (Koob model) explains the transition from impulsive to compulsive drinking.

Key Neurotransmitter Systems

GABA: alcohol is a positive allosteric modulator at GABA-A receptors; chronic use leads to GABA-A receptor downregulation. Glutamate: alcohol inhibits NMDA receptors; chronic use leads to NMDA receptor upregulation -- this compensatory change drives withdrawal excitotoxicity. Dopamine: alcohol increases dopamine release in the nucleus accumbens; chronic use leads to dopamine deficit state contributing to anhedonia. Opioid system: alcohol stimulates endogenous opioid (beta-endorphin) release; mediates rewarding effects; basis for naltrexone treatment. Corticotropin-releasing factor (CRF): stress system recruitment drives negative reinforcement in later stages of addiction.

Pharmacotherapy for Alcohol Use Disorder

Naltrexone

Mechanism: opioid receptor antagonist (mu, kappa); blocks alcohol-induced endorphin release, reducing the rewarding effects of drinking. Available formulations: oral 50 mg daily; extended-release IM injection (Vivitrol) 380 mg monthly. Evidence: COMBINE study (2006) showed naltrexone + medical management was effective; reduced heavy drinking days and relapse rate. Best candidates: strong craving, reward-driven drinking, family history of alcoholism, goal of reduced drinking. Contraindications: current opioid use (will precipitate withdrawal), acute hepatitis or hepatic failure, need for opioid analgesia. Check LFTs at baseline; hepatotoxicity risk is dose-dependent but rare at therapeutic doses. Injectable naltrexone may improve adherence compared to oral.

Acamprosate

Mechanism: modulates glutamatergic (NMDA) and GABAergic transmission; thought to restore the excitatory/inhibitory balance disrupted by chronic alcohol use. Dose: 666 mg TID (challenging dosing schedule) Evidence: European trials showed efficacy in maintaining abstinence; US COMBINE trial did not show superiority over placebo (potentially due to patient population differences) Best candidates: patients with goal of complete abstinence, those with prominent anxiety/dysphoria in early sobriety. Advantages: renally excreted, no hepatic metabolism (safe in liver disease), no abuse potential. Contraindications: severe renal impairment (CrCl < 30)

Disulfiram

Mechanism: irreversible inhibitor of aldehyde dehydrogenase; causes accumulation of acetaldehyde if alcohol is consumed, producing the disulfiram-ethanol reaction (flushing, nausea, vomiting, tachycardia, hypotension) Dose: 250-500 mg daily. Evidence: works primarily through psychological deterrence; most effective when adherence is supervised (observed dosing) Best candidates: highly motivated patients with external accountability (e.g., court-ordered, spouse-observed) Limitations: no effect on craving; efficacy depends entirely on adherence; severe reactions possible (cardiovascular collapse in rare cases) Contraindications: severe cardiovascular disease, psychosis, significant hepatic impairment, metronidazole use.

Comparison of AUD Pharmacotherapies

Other Pharmacologic Options

Topiramate: reduces glutamate and enhances GABA; evidence from multiple RCTs showing reduced heavy drinking; not FDA-approved for AUD but recommended in some guidelines; dose up to 300 mg/day; cognitive side effects and weight loss. Gabapentin: may reduce craving and improve sleep; some guideline support especially for patients with prominent insomnia/anxiety in early recovery; not FDA-approved for AUD. Baclofen: GABA-B agonist; mixed trial results; approved for AUD in France but not in the US. Nalmefene: opioid antagonist similar to naltrexone; approved in Europe for as-needed use to reduce heavy drinking; not approved in the US.

The COMBINE Study (2006)

Landmark NIAAA-funded trial: ~1,400 patients randomized across 9 treatment groups. Compared naltrexone, acamprosate, combined pharmacotherapy, CBI (specialized behavioral intervention), and medical management. Key findings: Naltrexone + medical management was effective (reduced heavy drinking) Acamprosate showed no advantage over placebo in this US population. CBI (behavioral intervention) added benefit when used without medication. Naltrexone + acamprosate combination was NOT superior to naltrexone alone.

<image> A diagram illustrating Koob's three-stage cycle of alcohol addiction. Three interconnected stages shown in a circle: (1) Binge/Intoxication (positive reinforcement, mesolimbic dopamine, opioid release, nucleus accumbens), (2) Withdrawal/Negative Affect (negative reinforcement, GABA downregulation, glutamate upregulation, CRF/stress system activation, extended amygdala), and (3) Preoccupation/Anticipation (craving, prefrontal cortex dysfunction, loss of executive control, glutamate projections). Show the transition from impulsive to compulsive drinking. Label the neurotransmitter systems involved at each stage. Neuroscience education style. </image>

<image> A comparison table of FDA-approved pharmacotherapies for alcohol use disorder. Three columns for naltrexone, acamprosate, and disulfiram. Rows: mechanism of action, formulations and dosing, key evidence, best candidate profile, contraindications, monitoring requirements, effect on craving, and common side effects. Include a note about topiramate and gabapentin as off-label options. Clinical reference format. </image>

<image> A flowchart for pharmacotherapy selection in alcohol use disorder. Start with "AUD diagnosed -- patient interested in pharmacotherapy." Branch by treatment goal: "Reduce heavy drinking" (naltrexone, especially IM form; topiramate) vs. "Achieve/maintain abstinence" (naltrexone, acamprosate, disulfiram with supervised dosing). Include decision nodes for liver disease (favor acamprosate), concurrent opioid use (avoid naltrexone), need for supervised deterrence (disulfiram). Show COMBINE study key findings in a callout box. Color-coded clinical algorithm. </image>

Clinical Pearls

Only ~7% of patients with AUD receive treatment -- every clinical encounter is an opportunity to screen and intervene. The AUDIT-C (3 items) is efficient for screening in busy clinical settings; a positive screen should prompt a full assessment. Naltrexone works best for reducing heavy drinking in reward-driven drinkers; it does NOT require abstinence before starting -- patients can begin while still drinking. Acamprosate is renally excreted and safe in liver disease -- use it when hepatic impairment precludes naltrexone or disulfiram. Disulfiram only works if the patient takes it -- supervised dosing (by a spouse, clinic, or probation officer) dramatically improves outcomes. Do not wait for patients to "hit bottom" before offering pharmacotherapy -- early intervention at lower severity levels is more effective. The COMBINE study showed naltrexone + medical management is effective even without specialized behavioral therapy -- any prescriber can offer this treatment.

References

• Anton RF, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study. JAMA. 2006;295(17):2003-2017.
• Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3(8):760-773.
• Jonas DE, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889-1900.
• Saunders JB, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT). Addiction. 1993;88(6):791-804.
• Reus VI, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175(1):86-90.

Read this lecture as Markdown